The group found that MCT1 nuclear positivity correlated with an increased OS of soft-tissue sarcoma patients; when it was expressed at the plasma membrane of cancer cells, MCT1 correlated with a decrease in OS. This evidence concerns the gene SLC16A1 and soft tissue sarcoma.